REFERENCES
- Nash TE, Cheever AW, Ottensen EA, Cook JA. Schistosomal infections in humans: perspectives and recent findings. Ann Intern Med 1982; 97: 740–754.
- Freidheim EAH. In ‘Chemotherapy of Schistosomiasis’, Cavier R and Hawkin F ( eds); Oxford Pergamon Press, 1973.
- Katz N, Grimbaum E, Chaves A, Zicker F, Pellegrino J. Clinical trials with oxamniquine by the oral route in Schistosomiasis mansoni. Rev Inst Med Trop Sao Paulo, 1976; 18: 371–377.
- Keystone JS. Seizures and electroencephalographic changes associated with oxamniquine. Am J Trop Med Hyg 1978; 27: 360–362.
- De Carvalho SA, Shikanai-Yasuda MA, Neto VA, Shiromo, M. Luccas, FJ. Neurotoxicidade do oxamniquine no tratamenti da infeccao humana pela Scistosoma mansoni. Rev Inst Med Trop Sao Paulo 1985; 27: 132–142
- Stokvis H, Bauer AGC, Stuiver PC, Malcolm AD, Overbosch D. Siezures associated with oxamniquine therapy. Am J Trop Med Hyg 1986; 35: 330–331.
- Kokwaro O, Taylor G. Partitioning of oxamniquine into brain tissue following intravenous administration to female rats. Drug Chem Tox 1990; 13: 347–54.
- Angel A, Clarke KA, Dewhurst DG. A pharmacological study of the spontaneous convulsive activity induced by 1,2-dihydroxybenzene (catechol) in the anaesthetised mouse. Br J Pharmacol 1977; 61: 433–9.